| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Black Bird Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.0007 |
| 52 Week Low | US$0.000001 |
| Beta | 2.74 |
| 1 Month Change | 19,900.00% |
| 3 Month Change | 100.00% |
| 1 Year Change | -50.00% |
| 3 Year Change | -99.35% |
| 5 Year Change | n/a |
| Change since IPO | -99.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| BBBT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 33.3% | -1.5% | -3.2% |
| 1Y | -50.0% | 9.7% | 19.3% |
Return vs Industry: BBBT underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: BBBT underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| BBBT volatility | |
|---|---|
| BBBT Average Weekly Movement | 8,696.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BBBT's share price has been volatile over the past 3 months.
Volatility Over Time: BBBT's weekly volatility has increased from 4932% to 8697% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Nelson Grist | www.blackbirdbiotech.com |
Black Bird Biotech Inc. provides various biotech products. It manufactures and distributes MiteXstream, a plant-based biopesticide for the eradication of spider mites. The company also manufactures and sells CBD Oils, gummies and pet treats, CBD-infused personal care products, and hand sanitizer under the Grizzly Creek Naturals brand name.
Black Bird Biotech, Inc. Fundamentals Summary
| BBBT fundamental statistics | |
|---|---|
| Market cap | US$596.38k |
| Earnings (TTM) | -US$836.13k |
| Revenue (TTM) | US$36.32k |
16.4x
P/S Ratio-0.7x
P/E RatioIs BBBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBBT income statement (TTM) | |
|---|---|
| Revenue | US$36.32k |
| Cost of Revenue | US$49.62k |
| Gross Profit | -US$13.29k |
| Other Expenses | US$822.84k |
| Earnings | -US$836.13k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00028 |
| Gross Margin | -36.60% |
| Net Profit Margin | -2,301.94% |
| Debt/Equity Ratio | -99.4% |
How did BBBT perform over the long term?
See historical performance and comparison